title: A two year observation of the process of applying recombinant IGF-1 to treat short stature in children with primary IGF-1 deficiency -- case reports of 3 patients.
abstract: Growth deficiency is one of the most frequent causes of referral to Endocrinology Outpatient Clinic. IGF-1 (insulin-like growth factor 1) deficiency is one of the rarest causes of short stature. In 2009 in Poland a therapeutic programme was set up for children with severe primary IGF-1 deficiency. The authors present the data of three first polish patients qualified for the rhIGF-1 (recombinant human insulin-like growth factor 1) - mecasermin. The authors conclude that the treatment with rhIGF-1 significantly improves growth velocity in patients with IGF-1 deficiency. During two years of mecasermin treatment no serious side effects were noted.
authors.affiliation: Department of Pediatrics, Endocrinology, Diabetology, Metabolic Diseases and Cardiology of the Developmental Age, Pomeranian Medical University, Szczecin, Poland. elzbietapetriczko@gmail.com
authors.forename: Elżbieta
authors.initials: E
authors.lastname: Petriczko
authors.forename: Beata
authors.initials: B
authors.lastname: Wikiera
authors.forename: Anita
authors.initials: A
authors.lastname: Horodnicka-Józwa
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Marcinkiewicz
authors.forename: Justyna
authors.initials: J
authors.lastname: Szmit-Domagalska
authors.forename: Andrzej
authors.initials: A
authors.lastname: Kędzia
authors.forename: Julia
authors.initials: J
authors.lastname: Durzyńska
authors.forename: Justyna
authors.initials: J
authors.lastname: Broniarczyk
authors.forename: Bartosz
authors.initials: B
authors.lastname: Gabryelczyk
authors.forename: Anna
authors.initials: A
authors.lastname: Noczyńska
authors.forename: Mieczysław
authors.initials: M
authors.lastname: Walczak
mesh_terms: D000293:Adolescent; D001827:Body Height / Q000187:drug effects; D002648:Child; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006130:Growth Disorders / Q000097:blood* / Q000188:drug therapy*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000172:deficiency* / Q000627:therapeutic use; D036341:Intercellular Signaling Peptides and Proteins / Q000008:administration & dosage*; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D036341:Intercellular Signaling Peptides and Proteins; D011994:Recombinant Proteins; C065700:myotrophin; D007334:Insulin-Like Growth Factor I